Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-02-18 Sale |
2025-02-20 5:14 pm |
Neumora Therapeutics Inc. | NMRA | BERNS PAUL L See Remarks |
13,871 | $1.6919 | $23,468 | 7,804,295 (Indirect Direct) |
View |
| 2025-02-18 Sale |
2025-02-20 5:14 pm |
Neumora Therapeutics Inc. | NMRA | Milligan Michael Lee See Remarks |
1,978 | $1.6939 | $3,351 | 22,470 (Direct) |
View |
| 2025-02-18 Sale |
2025-02-20 5:13 pm |
Neumora Therapeutics Inc. | NMRA | Aurora Daljit Singh Chief Strategy Officer |
8,565 | $1.6751 | $14,347 | 203,638 (Indirect Direct) |
View |
| 2025-02-18 Sale |
2025-02-20 5:12 pm |
Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D |
5,614 | $1.6714 | $9,383 | 309,092 (Direct) |
View |
| 2025-02-18 Sale |
2025-02-20 5:11 pm |
Neumora Therapeutics Inc. | NMRA | Pinto Joshua President |
8,048 | $1.6746 | $13,477 | 215,917 (Indirect Direct) |
View |
| 2024-10-17 Sale |
2024-10-18 6:25 pm |
Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director |
21,788 | $17.03 | $370,962 | 205,321 (Direct) |
View |
| 2024-10-09 Sale |
2024-10-11 4:10 pm |
Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D |
13,823 | $15.06 | $208,110 | 314,706 (Direct) |
View |
| 2024-09-17 Sale |
2024-09-19 4:35 pm |
Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D |
41,464 | $11.89 | $492,827 | 328,529 (Direct) |
View |
| 2024-09-12 Sale |
2024-09-16 4:05 pm |
Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D |
32,948 | $11.43 | $376,665 | 369,993 (Direct) |
View |
| 2024-08-27 Sale |
2024-08-27 5:58 pm |
Neumora Therapeutics Inc. | NMRA | Pinto Joshua Chief Financial Officer |
15,693 | $11.39 | $178,806 | 223,965 (Indirect Direct) |
View |
| 2024-08-22 Sale |
2024-08-26 6:17 pm |
Neumora Therapeutics Inc. | NMRA | Pinto Joshua Chief Financial Officer |
84,307 | $11.67 | $984,061 | 239,658 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2035-02-13 |
Neumora Therapeutics Inc. | NMRA | BERNS PAUL L See Remarks |
3,795,413 | $0 | 3,795,413 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2031-04-23 |
Neumora Therapeutics Inc. | NMRA | Ho Maykin Director |
151,959 | $0 | 151,959 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2033-09-14 |
Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D |
602,934 | $0 | 602,934 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2035-02-13 |
Neumora Therapeutics Inc. | NMRA | Aurora Daljit Singh See Remarks |
1,819,497 | $0 | 1,819,497 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2031-04-23 |
Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director |
141,959 | $0 | 141,959 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2033-09-14 |
Neumora Therapeutics Inc. | NMRA | Piacquad David Director |
75,026 | $0 | 75,026 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2033-09-14 |
Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner |
75,026 | $0 | 75,026 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2035-02-13 |
Neumora Therapeutics Inc. | NMRA | Milligan Michael Lee See Remarks |
593,550 | $0 | 593,550 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2035-02-13 |
Neumora Therapeutics Inc. | NMRA | Pinto Joshua President |
4,734,428 | $0 | 4,734,428 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2035-02-13 |
Neumora Therapeutics Inc. | NMRA | Duncan Jason See Remarks |
900,000 | $0 | 900,000 (Direct) |
View |
| 2025-02-13 Option Award |
2025-02-18 4:30 pm |
N/A 2033-09-14 |
Neumora Therapeutics Inc. | NMRA | Halawa Alaa Director |
75,026 | $0 | 75,026 (Direct) |
View |
| 2024-12-27 Gift |
2024-12-27 5:01 pm |
N/A N/A |
Neumora Therapeutics Inc. | NMRA | BERNS PAUL L Director |
133,097 | $0 | 7,818,166 (Direct) |
View |
| 2024-10-17 Exercise |
2024-10-18 6:25 pm |
N/A 2030-09-07 |
Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director |
21,788 | $0 | 205,321 (Direct) |
View |
| 2024-10-17 Exercise |
2024-10-18 6:25 pm |
N/A N/A |
Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director |
8,005 | $8.79 | 205,321 (Direct) |
View |
| 2024-10-17 Exercise |
2024-10-18 6:25 pm |
N/A N/A |
Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director |
3,783 | $8.32 | 205,321 (Direct) |
View |
| 2024-10-17 Exercise |
2024-10-18 6:25 pm |
N/A N/A |
Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director |
10,000 | $2.52 | 205,321 (Direct) |
View |
| 2024-09-12 Gift |
2024-09-13 5:22 pm |
N/A 2031-09-20 |
Neumora Therapeutics Inc. | NMRA | Aurora Daljit Singh Chief Strategy Officer |
606,970 | $0 | 836,700 (Direct) |
View |
| 2024-04-17 Gift |
2024-06-28 9:00 pm |
N/A N/A |
Neumora Therapeutics Inc. | NMRA | Pinto Joshua Chief Financial Officer |
238,965 | $0 | 323,965 (Indirect) |
View |
| 2024-06-13 Option Award |
2024-06-14 4:18 pm |
N/A 2034-06-12 |
Neumora Therapeutics Inc. | NMRA | Ho Maykin Director |
48,671 | $0 | 48,671 (Direct) |
View |
| 2024-06-13 Option Award |
2024-06-14 4:16 pm |
N/A 2034-06-12 |
Neumora Therapeutics Inc. | NMRA | Piacquad David Director |
48,671 | $0 | 48,671 (Direct) |
View |
| 2024-06-13 Option Award |
2024-06-14 4:14 pm |
N/A 2034-06-12 |
Neumora Therapeutics Inc. | NMRA | Halawa Alaa Director |
48,671 | $0 | 48,671 (Direct) |
View |
| 2024-06-13 Option Award |
2024-06-14 4:13 pm |
N/A 2034-06-12 |
Neumora Therapeutics Inc. | NMRA | Fust Matthew K Director |
48,671 | $0 | 48,671 (Direct) |
View |
| 2024-06-13 Option Award |
2024-06-14 4:11 pm |
N/A 2034-06-12 |
Neumora Therapeutics Inc. | NMRA | Burow Kristina Director 10% Owner |
48,671 | $0 | 32,008,426 (Direct) |
View |
| 2024-04-22 Gift |
2024-04-24 5:00 pm |
N/A N/A |
Neumora Therapeutics Inc. | NMRA | Aurora Daljit Singh Chief Strategy Officer |
114,703 | $0 | 212,203 (Direct) |
View |
| 2024-02-14 Option Award |
2024-02-16 4:21 pm |
N/A 2034-02-13 |
Neumora Therapeutics Inc. | NMRA | Pinto Joshua Chief Financial Officer |
255,000 | $0 | 493,965 (Direct) |
View |
| 2024-02-14 Option Award |
2024-02-16 4:20 pm |
N/A 2034-02-13 |
Neumora Therapeutics Inc. | NMRA | Aurora Daljit Singh Chief Strategy Officer |
292,500 | $0 | 407,203 (Direct) |
View |
| 2024-02-14 Option Award |
2024-02-16 4:19 pm |
N/A 2034-02-13 |
Neumora Therapeutics Inc. | NMRA | Suh Carol Y. Chief Operating Officer |
255,000 | $0 | 544,674 (Direct) |
View |
| 2024-02-14 Option Award |
2024-02-16 4:17 pm |
N/A 2034-02-13 |
Neumora Therapeutics Inc. | NMRA | BERNS PAUL L Director |
513,750 | $0 | 8,160,666 (Direct) |
View |
| 2024-02-14 Option Award |
2024-02-16 4:15 pm |
N/A 2034-02-13 |
Neumora Therapeutics Inc. | NMRA | Gosebruch Henry O President & CEO |
240,000 | $0 | 764,793 (Direct) |
View |
| 2024-02-14 Option Award |
2024-02-16 4:14 pm |
N/A 2034-02-13 |
Neumora Therapeutics Inc. | NMRA | Milligan Michael Lee See Remarks |
61,875 | $0 | 65,698 (Direct) |
View |
| 2024-02-14 Option Award |
2024-02-16 4:13 pm |
N/A 2034-02-13 |
Neumora Therapeutics Inc. | NMRA | Lenz Robert A. Head of R&D |
150,000 | $0 | 502,941 (Direct) |
View |
| 2023-12-08 Other |
2023-12-12 7:53 pm |
N/A N/A |
Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners XII LLC ARCH Venture Partners XII L.P. ARCH Venture Fund XII L.P. CRANDELL KEITH GILLIS STEVEN NELSEN ROBERT BYBEE CLINTON 10% Owner |
1,879,654 | $0 | 32,424,564 (Indirect) |
View |
| 2023-12-08 Other |
2023-12-12 7:52 pm |
N/A N/A |
Neumora Therapeutics Inc. | NMRA | ARCH Venture Partners X LLC ARCH Venture Fund X L.P. ARCH Venture Partners X L.P. ARCH Venture Fund X Overage L.P. ARCH Venture Partners X Overage L.P. ARCH Venture Partners VII LLC ARCH Venture Partners VII L.P. ARCH Venture Fund VII L.P. ARCH Venture Partners VIII LLC ARCH Venture Fund VIII Overage L.P. 10% Owner |
1,879,654 | $0 | 32,424,564 (Indirect) |
View |